Highlights Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
28.12 ^USD	+0.43%		+1.08%	+0.11%

Apr. 17	Royalty Pharma Maintains Quarterly Dividend at $0.21 per Share, Payable June 14 to Shareholders of Record May 17	MT
Apr. 17	Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Royalty Pharma Maintains Quarterly Dividend at $0.21 per Share, Payable June 14 to Shareholders of Record May 17	Apr. 17	MT
Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024	Apr. 17	CI
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on March 28, 2023.	Feb. 15	CI
Royalty Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Royalty Pharma Swings to Q4 Net Income, Revenue Increases	Feb. 15	MT
Royalty Pharma plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Earnings Flash (RPRX) ROYALTY PHARMA Reports Q4 Revenue $596M, vs. Street Est of $674.5M	Feb. 15	MT
Novartis wants to swallow Morphosys - access to beacon of hope	Feb. 06	DP
Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG for ?2.7 billion.	Feb. 04	CI
Royalty Pharma Raises Quarterly Dividend by 5% to $0.21 per Class A Share, Payable March 15 to Shareholders of Record on Feb. 16	Jan. 19	MT
Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024	Jan. 19	CI
PureTech Health Provides Updates on Programs, Reports Strong Financial Position	Dec. 20	MT
Morphosys raises more than 100 million euros with capital increase	Dec. 14	DP
MORPHOSYS IN FOCUS: The shaken belief in a blockbuster	Nov. 22	DP
Teva Pharmaceuticals International GmbH and Royalty Pharma plc Collaborate to Further Accelerate Olanzapine LAI Program	Nov. 13	CI
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on March 28, 2023.	Nov. 08	CI
Royalty Pharma plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Royalty Pharma's Q3 Net Income, Revenue Decline	Nov. 08	MT
Earnings Flash (RPRX) ROYALTY PHARMA Reports Q3 Revenue $536M, vs. Street Est of $618.5M	Nov. 08	MT
Royalty Pharma to Buy Additional Royalties on Roche's Neuromuscular Disease Drug for $1 Billion	23-10-19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Highlights

Filters